Advertisement
Singapore markets close in 4 hours 50 minutes
  • Straits Times Index

    3,286.44
    -1.31 (-0.04%)
     
  • Nikkei

    37,905.29
    +276.81 (+0.74%)
     
  • Hang Seng

    17,618.38
    +333.84 (+1.93%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,354.86
    +171.50 (+0.27%)
     
  • CMC Crypto 200

    1,390.52
    +7.94 (+0.57%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,346.80
    +4.30 (+0.18%)
     
  • Crude Oil

    83.81
    +0.24 (+0.29%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,573.52
    +4.27 (+0.27%)
     
  • Jakarta Composite Index

    7,113.43
    -41.86 (-0.59%)
     
  • PSE Index

    6,566.48
    -8.40 (-0.13%)
     

Inside Depomed’s Portfolio: The Key Drugs

Inside Depomed’s Portfolio: The Key Drugs

Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.